{"id":249845,"date":"2023-07-07T00:00:00","date_gmt":"2023-07-07T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidne0008-biopharma-membranous-nephropathy-epidemiology-middle\/"},"modified":"2026-04-23T11:24:20","modified_gmt":"2026-04-23T11:24:20","slug":"epidne0008-biopharma-membranous-nephropathy-epidemiology-middle-east-and-africa","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidne0008-biopharma-membranous-nephropathy-epidemiology-middle-east-and-africa\/","title":{"rendered":"Membranous Nephropathy &#8211; Epidemiology &#8211; Middle East and Africa"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of membranous nephropathy (<abbr title=\"membranous nephropathy\">MN<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of <abbr title=\"membranous nephropathy\">MN<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"membranous nephropathy\">MN<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How many cases of <abbr title=\"membranous nephropathy\">MN<\/abbr> in the countries under study have been formally diagnosed?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"membranous nephropathy\">MN<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"membranous nephropathy\">MN<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incidence of <abbr title=\"membranous nephropathy\">MN<\/abbr>.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"membranous nephropathy\">MN<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249845","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-geography-middle-east-africa","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249845\/revisions"}],"predecessor-version":[{"id":281453,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249845\/revisions\/281453"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}